Syndax Pharmaceuticals Operating Income

Syndax Pharmaceuticals (SNDX) currently reports a operating income of $-190M as of June 2026. That compares with $-340M in the prior-year period — up 42.7% year over year. Use the charts on this page to explore Syndax Pharmaceuticals's operating income history and peer comparisons.

Syndax Pharmaceuticals's operating income increased from $-340M to $-190M — a 42.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Syndax Pharmaceuticals reported $-190M in operating income as of June 2026. That compares with $-340M in the prior-year period — up 42.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-190M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Syndax Pharmaceuticals, and consider following SNDX for alerts when major investors trade the stock.

Syndax Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-190M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SNDX with unrelated industries.